Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.85
FGEN's Cash to Debt is ranked lower than
73% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. FGEN: 1.85 )
Ranked among companies with meaningful Cash to Debt only.
FGEN' s 10-Year Cash to Debt Range
Min: 0.43   Max: 1.85
Current: 1.85

0.43
1.85
Equity to Asset 0.46
FGEN's Equity to Asset is ranked lower than
73% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FGEN: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
FGEN' s 10-Year Equity to Asset Range
Min: -0.3   Max: 0.46
Current: 0.46

-0.3
0.46
Z-Score: 2.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -274.41
FGEN's Operating margin (%) is ranked lower than
64% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. FGEN: -274.41 )
Ranked among companies with meaningful Operating margin (%) only.
FGEN' s 10-Year Operating margin (%) Range
Min: -41.29   Max: -7.78
Current: -274.41

-41.29
-7.78
Net-margin (%) -284.50
FGEN's Net-margin (%) is ranked lower than
66% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. FGEN: -284.50 )
Ranked among companies with meaningful Net-margin (%) only.
FGEN' s 10-Year Net-margin (%) Range
Min: -49.4   Max: -14.63
Current: -284.5

-49.4
-14.63
ROE (%) -22.84
FGEN's ROE (%) is ranked higher than
54% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. FGEN: -22.84 )
Ranked among companies with meaningful ROE (%) only.
FGEN' s 10-Year ROE (%) Range
Min: -89.68   Max: -89.68
Current: -22.84

ROA (%) -10.09
FGEN's ROA (%) is ranked higher than
62% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. FGEN: -10.09 )
Ranked among companies with meaningful ROA (%) only.
FGEN' s 10-Year ROA (%) Range
Min: -15.25   Max: -5.31
Current: -10.09

-15.25
-5.31
ROC (Joel Greenblatt) (%) -33.90
FGEN's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. FGEN: -33.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -38.24   Max: -12.24
Current: -33.9

-38.24
-12.24
» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FGEN Guru Trades in

FGEN Guru Trades in

FGEN Guru Trades in

Q1 2015

FGEN Guru Trades in Q1 2015

Joel Greenblatt 40,955 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.50
FGEN's P/B is ranked lower than
59% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. FGEN: 5.50 )
Ranked among companies with meaningful P/B only.
FGEN' s 10-Year P/B Range
Min: 4.8   Max: 9.19
Current: 5.5

4.8
9.19
P/S 2.40
FGEN's P/S is ranked higher than
88% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. FGEN: 2.40 )
Ranked among companies with meaningful P/S only.
FGEN' s 10-Year P/S Range
Min: 2.4   Max: 4.7
Current: 2.4

2.4
4.7
PFCF 23.00
FGEN's PFCF is ranked higher than
69% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. FGEN: 23.00 )
Ranked among companies with meaningful PFCF only.
FGEN' s 10-Year PFCF Range
Min: 23   Max: 45.37
Current: 23

23
45.37
POCF 15.13
FGEN's POCF is ranked higher than
78% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 31.64 vs. FGEN: 15.13 )
Ranked among companies with meaningful POCF only.
FGEN' s 10-Year POCF Range
Min: 15.13   Max: 28.97
Current: 15.13

15.13
28.97
Current Ratio 3.16
FGEN's Current Ratio is ranked lower than
60% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. FGEN: 3.16 )
Ranked among companies with meaningful Current Ratio only.
FGEN' s 10-Year Current Ratio Range
Min: 2.23   Max: 3.83
Current: 3.16

2.23
3.83
Quick Ratio 3.16
FGEN's Quick Ratio is ranked lower than
57% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. FGEN: 3.16 )
Ranked among companies with meaningful Quick Ratio only.
FGEN' s 10-Year Quick Ratio Range
Min: 2.23   Max: 3.83
Current: 3.16

2.23
3.83
Days Sales Outstanding 155.94
FGEN's Days Sales Outstanding is ranked lower than
84% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. FGEN: 155.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
FGEN' s 10-Year Days Sales Outstanding Range
Min: 22.33   Max: 48.63
Current: 155.94

22.33
48.63

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.60
FGEN's Price/Tangible Book is ranked higher than
57% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. FGEN: 5.60 )
Ranked among companies with meaningful Price/Tangible Book only.
FGEN' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 5.6

Price/Median PS Value 0.60
FGEN's Price/Median PS Value is ranked higher than
84% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. FGEN: 0.60 )
Ranked among companies with meaningful Price/Median PS Value only.
FGEN' s 10-Year Price/Median PS Value Range
Min: 0.93   Max: 0.93
Current: 0.6

Earnings Yield (Greenblatt) -5.10
FGEN's Earnings Yield (Greenblatt) is ranked higher than
58% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. FGEN: -5.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
FGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.3   Max: 0
Current: -5.1

-5.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:1FG.Germany, FGEN.Mexico,
FibroGen Inc was incorporated in 1993 in Delaware. It is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Company's focus in the areas of fibrosis and hypoxia-inducible factor biology has generated multiple programs targeting various therapeutic areas. Its product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases ("HIF-PHs"), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). FG-3019 is the Company's monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer and liver fibrosis. The Company's business area includes Europe and Japan. Certain of the components of its product candidates are acquired from single-source suppliers and have been purchased without long-term supply agreements. The Comapny do not have an alternative supplier of certain components of their product candidates. The Company faces competition from multiple other pharmaceutical and biotechnology companies, many of which have greater financial, technical and human resources and experience in product development, manufacturing and marketing. Its trademarks include "FibroGen". The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of its product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for FGEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FibroGen to Webcast Presentation at the Goldman Sachs Global Healthcare Conference Jun 01 2015
FibroGen to Webcast Presentation at the Goldman Sachs Global Healthcare Conference Jun 01 2015
FIBROGEN INC Financials May 20 2015
PHILIPPINE STAR: First Gen to boost hydropower portfolio May 19 2015
STANDARD: First Gen readies LNG hub May 19 2015
MANILA BULLETIN: First Gen income up 17% to .5M May 19 2015
MANILA BULLETIN: First Gen’s board gets fresh mandate from stockholders May 19 2015
FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 13 2015
FibroGen Announces First Quarter 2015 Financial Results May 12 2015
FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 12 2015
FibroGen Announces First Quarter 2015 Financial Results May 12 2015
FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 07 2015
FibroGen Announces Receipt of Milestone Payment from AstraZeneca for Successful Completion of... May 07 2015
FibroGen Announces Receipt of Milestone Payment from AstraZeneca for Successful Completion of... May 07 2015
FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure May 01 2015
FibroGen Inc Earnings Call scheduled for 4:30 pm ET today Mar 26 2015
FibroGen Announces 2014 Financial Results and Provides Corporate Update Mar 26 2015
FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 26 2015
FibroGen Announces 2014 Financial Results and Provides Corporate Update Mar 26 2015
Q4 2014 FibroGen Inc Earnings Release - After Market Close Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK